Results:
RSK4 is frequently hypermethylated in endometrial cancer cells lines and in primary endometrial cancer compared to normal endometrial tissue. RSK4 methylation was significantly associated with tumor grade, with higher grade tumors having lower levels of methylation (p=0.03). RSK4 methylation levels were not associated with other clinical variables. We did find that RSK4 methylation was significantly correlated with expression in primary endometrial tumors and in cell lines. Re-activation of RSK4 by 5-azacytidine was successfully performed showing 8 to >1,200 fold increases in transcript levels.
Conclusion: RSK4 appears to be epigenetically silenced in endometrial cancer as evidenced by hypermethylation. Its role as suppressor in endometrial cancer, however, remains uncertain.
TRANSLATIONAL RELEVANCE
Novel therapies targeting specific pathways in endometrial cancer hold promise for better outcomes. Our work demonstrates the first known research of RSK4 in endometrial cancer. RSK4 is a putative tumor suppressor gene and its regulation has been demonstrated as a potential target in other cancers. Our study evaluated the methylation of RSK4 in a large set of well characterized endometrial cancer tissues, obtained from our clinical patient base. We found a correlation with methylation and tumor grade. As tumor grade is one of the most powerfully predictive clinical features of this disease, we sought to evaluate this molecular phenotype of methylation with a potential clinically used treatment of 5aza-cytadine. Our work shows a direct effect of demethylation on RSK4 which returns the expression to wild-type. This work could lead to further investigation of RSK4 as a potential target in the treatment of endometrial cancer.
INTRODUCTION
In the United States, endometrial cancer is the most common malignancy of the female genital tract. It is estimated that 42,160 women were diagnosed with this disease in 2009, resulting in 7,780 deaths (1). Fortunately, the majority of endometrial cancer is diagnosed at an early stage due to abnormal uterine bleeding, and most of these women are cured with surgery. However, the prognosis for patient with advanced stage and recurrent endometrial cancers is poor with an approximate 12 month median overall survival (2) . Effective treatments for these advanced cancers are lacking, and the chemotherapy regimens most commonly used have high toxicities.
Targeted therapies that come from study of cancer biology hold promise for more specific and effective treatments and less toxicity than is seen with conventional cytoxic chemotherapy. The FGFR2/RAS/ERK signaling pathway is frequently activated in endometrial cancers (3, 4) . A number of components of the signaling cascade (FGRFR2, ras, and MEK) have been or are currently being evaluated as targets for therapy. RPS6KA6 (RSK4) is an ERK substrate (5) . RSK4 has been identified as a modulator of p53-dependent proliferation arrest in human cells and has been shown to inhibit transcriptional activation of specific targets of receptor tyrosine kinase (RTK) signaling as well as activation of ERK (6) . It also has been implicated as a tumor suppressor gene, showing tumor suppressor activities in breast, colon and renal carcinomas (7) (8) (9) . RSK4 overexpressing mammary tumors in transgenic mice are noninvasive and do not metastasize (10) . Furthermore, in breast cancer cell lines, RSK4 overexpression decreased proliferation and invasive ability (10) . Finally, down regulation of RSK4 has been seen in primary human colon cancer (11) .
Research. RSK4 is located on the X-chromosome (Xq21.1) and subject to X-inactivation. It is part of the p90 ribosomal S6 kinase family, which includes both activating and inhibitory isoforms RSK1, RSK2, RSK3, RSK4. RSK4 play a role in the in regulation of cellular division, survival, and differentiation via substrate phosphorylation. It appears to be constitutively activated in cells, may function to suppress FGFR2-RAS-ERK signal transduction and cell proliferation. Its expression may be one mechanism to restrict cell growth (12) .
We found that RSK4 is expressed in normal uterine tissue and is absent or much reduced in endometrial cancer (cell lines and primary tumors). Given the high frequency of the so-called CpG island methylator phenotype in endometrial cancers and that RSK4 is an X-linked gene and normally subject to methylated mediated gene silencing, we sought to determine if the aberrant CpG methylation could explain loss of expression.
We hypothesized that the absence of RSK4 transcript is associated with epigenetic silencing in endometrial cancers.
MATERIALS and METHODS

Patient samples
Primary endometrial tumor tissues, normal endometrium and normal blood specimens Representative portions of tumors were formalin fixed, paraffin embedded and histologically evaluated. DNA and RNA were prepared from tumor tissues with > 70% neoplastic cellularity. Tumor DNA was prepared using proteinase K and phenol extraction or with the DNeasy Tissue Kit (Qiagen Inc, Valencia, CA). DNA was extracted from peripheral-blood leukocytes as previously described (13) . Total RNA was extracted from cell lines and primary tissues using Trizol ® (Invitrogen, Carlsbad, CA).
Combined bisulfite restriction analysis (COBRA) and bisulfite sequencing
Bisulfite conversion of cell line and primary tissue DNAs was performed using EZ DNA Methylation-Gold™ Kit reagents (Zymo Research, Orange, CA). RSK4 sequences of interest were amplified using two rounds of PCR amplification (nested PCR). Primers, amplicon sizes, and restriction enzymes used are presented in Table 1 .
Following digestion with the appropriate enzyme, restriction fragments were resolved on 10% polyacrylamide gels, stained with ethidium bromide, and photoimaged with a UV camera (ImageSTore 7500 Version 7.12, White/UV Transilluminator; UVP, Inc., Upland, CA). Band intensities were quantified using ImageJ (National Institutes of Health, Bethesda, MD) to estimate the percent methylation/digestion for a given restriction enzyme cut site.
Cloning and sequencing of bisulfite converted tumor and normal DNAs was preformed using standard methods (14) . PCR products were cloned using the PCR-2.1TOPO TA vector (Invitrogen, Carlsbad, CA) and a minimum of seven clones for each cloning experiment sequenced using ABI Prism BigDye ® Terminator chemistry v1.1 (Applied Biosystems, Foster City, CA).
Research. 
Statistical analysis
For the analysis of primary tumors, RSK4 promoter methylation was categorized into 3 groups according to the % ZraI site methylation: <50%, 50-75%, and >75%. The associations between RSK4 methylation status and other demographic/clinical characteristics were assessed using Fisher exact test, analysis of variance (ANOVA) or Kruskall-Wallis rank-sum test as appropriate. The effect of RSK4 methylation on overall survival (OS) or disease-free survival (DFS) was described by Kaplan-Meier product limit method and compared using log-rank test. OS was defined as the time from the date of surgery to the date of death due to any causes, and survivors were censored at the date of last contact. DFS was defined as the time from the date of surgery to the date of recurrence or death, whichever occurred first. All analyses were two-sided and significance was set at a p-value of 0.05. Statistical analyses were performed using statistical package SAS (SAS Institutes, Cary, NC).
RESULTS
Methylation status of the promoter region of RSK4 (RPS6KA6)
Normal DNAs
We analyzed the ~ 1000bp RSK4 CpG island for methylation using combined bisulfite restriction analysis (COBRA). Three overlapping assays 5' of exon 1 and two from intron 1 were evaluated in DNAs prepared from normal blood and endometrium to determine the patterns of methylation seen in noncancerous tissues. A ZraI restriction site Analysis of an expanded cohort of normal male (N=12) and female (N=34) DNAs assessing methylation at the ZraI site (GACGTC), using the optimized assay #10, gave a mean % methylation of 0.7% and 40%, respectively (range 0.2 to 2% for males and 25-59% for females). proximal CpG pairs (referred as sites [12] [13] [14] were, however, significantly less methylated in both normal female blood DNA and tumors compared to the more 5' CpG pairs.
Cell lines and primary tumor DNAs
Given the proximal CpGs in the region may not be methylated on the inactive X chromosome we focused our DNA methylation on the ZraI digestions. We recognize that a more detailed analysis of methylation could reveal that there are other CpG dinucleotides that show a different methylation pattern. However, it has been our experience that in general, the methylation in a CpG Island is highly correlated with variation across the region.
RSK4 promoter methylation in primary tumors
Our initial exploratory studies on RSK4 methylation in a primary tumors revealed methylation levels were lower in higher grade tumors (grade 3 endometrioid cancers and uterine serous cancers). To better determine if RSK4 methylation is associated with clinicopathologic features we evaluated at total of 158 primary tumors (146 endometrioid cancers, 11 uterine papillary serous carcinomas (UPSC) and 1 mixed endometrioid/serous cancer). The clinical and molecular characteristics of the endometrioid patient population can be seen in Table 2 . The endometrioid primary tumors were selected for approximate equal distribution of grades to allow us to followup on the initial observation that high grade tumors appeared less methylated. The average methylation of the RSK4 promoter in primary endometrioid tumors as assessed by ZraI COBRA was 63% (range 3 to 96%). Serous cancers on the other hand were largely unmethylated ( Figure 1B ) with an average methylation of 18% (range 8 to 34%), less than expected for a normal female tissues with one active and one inactive X chromosome.
Research. Table 2 ). In addition, we did find that 40% of tumors with a high level of RSK4 methylation had either a KRAS2 or FGFR2 mutation but there was not a statistically significant association between methylation RSK4 and mutations in either gene or both combined. 
DISCUSSION
RSK4 is predominantly a cytosolic protein expressed a low levels in a broad range of human tissues (7, 11, 12, 17) . Dummler suppress ras-ERK signal transduction and cell proliferation (12) . Studies from LopezVicente and colleagues further implicated RSK4 as a tumor suppressor (7, 12) . RSK4 mRNA levels were shown to be lower in human colon and renal tumor tissues compared to their normal counterparts and protein levels were similarly reduced based on Western blot analysis. RSK4 transduction of colon carcinoma and primary fibroblasts cell lines (IMR90) induced cell growth arrest and RSK4 inhibition immortalized IMR90 cells.
Reduced RSK4 activity in the HCT116 colon cancer cell line was associated with a survival advantage when cell were exposed to DNA-damaging agents (7) . RSK4 contributions to cancer phenotypes could be through regulation of cell cycle arrest and stress responses (7), tumor invasiveness and metastasis (8, 10) .
Given the high frequency of activated ERK signaling in endometrial cancers (18-21) and RSK4's potential role in suppressing ERK signaling we hypothesized reduced RSK4 activity might contribute to endometrial tumorigenesis. RSK4 mutation is an infrequent event in cancer. Among 339 tumor specimens reported in the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic), only two missense changes are described (22) . Both mutations were seen in primary lung cancer (2 in 87 investigated) and involved the N terminal kinase. Given endometrial cancer frequently exhibit a CpG island methylator phenotype (23) we tested for increased methylation of the RSK4 CpG island in primary endometrial cancer and endometrial cancer cell lines. To the best of our knowledge there have been no prior studies on RSK4 methylation in endometrial cancers.
Because RSK4 is an X-linked gene subject to X-inactivation (24), our methylation analysis was focused on a region of the CpG island for which there was no methylation in normal male DNAs and ~50% methylation in normal female DNA. We observed both hyper-and hypomethylation of RSK4 promoter sequences in primary tumors and in endometrial cancer cell lines. In primary endometrial cancers, decreased RSK4 methylation was associated with deletion in 26% of the cases (8 of 31) investigated.
Loss of the inactive X chromosome (methylated) in such tumors would explain the low level RSK4 methylation. Loss of the inactive X chromosome and replication of the active X has been described in basal like breast cancers (25) . BRCA1 breast tumors (cancers with mutation in the BRCA1 tumor suppressor) have defects in X inactivation, genetic instability of the X chromosome and both gains and losses of the inactive X (26). The majority of primary endometrial tumors with low level RSK4 methylation (23 of 31, 74%), in our study did not appear to lose an X chromosome (or gain copies of the active X).
We speculate that loss of methylation at the RSK4 locus on the inactive X chromosome has occurred in these cases. Whether the gain in methylation at RSK4 in endometrioid endometrial cancer is part of a more general abnormality in X chromosome DNA methylation and chromatin modification or is associated with the CpG methylator phenotype remains to be determined. 
primary endometrial cancers have activation (pERK positivity) and that ERK activation is seen in the absence of KRAS2 and/or FGFR2 mutations (21) and our unpublished data.
It is possible that reduced RSK4 activity could explain ERK activity in a fraction of cases for which no mutational activation of the signaling cascade is seen.
The relationship between RSK4 methylation and tumor grade we observed was unexpected. Reduced levels of methylation in poorly differentiated (grade 3) endometrioid tumors could reflect as yet unappreciated differences in RSK4 activity and/or ERK signaling in well-differentiated vs. poorly differentiated tumors. The RSK family members phosphorylate a range of substrates important in malignancies (27) . 
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